Jiangsu Hengrui Pharmaceuticals (600276.SH) has initiated Phase III research on long-acting insulin combined with GLP-1 analog complex preparations.

On April 28th, the Drug Clinical Trial Registration and Information Disclosure Platform showed that Jiangsu Hengrui Pharmaceuticals (600276.SH) has initiated a randomized, open, parallel-controlled, Phase III clinical trial (CTR20241529) for HR17031 injection. The study aims to compare the effectiveness and safety of HR17031 injection with prandial insulin in type 2 diabetes patients with inadequate blood sugar control who are receiving metformin either alone or in combination with another oral hypoglycemic agent. The primary endpoint is the change in HbA1c relative to baseline at week 26. HR17031 is a proprietary fixed-ratio compound injection of long-acting basal insulin and GLP-1 analog developed by Hengrui for the treatment of type 2 diabetes. In July 2021, HR17031 was approved for clinical use in both the United States and China. In China, Hengrui leads the development of similar drugs, with HR17031 being the first domestically produced insulin + GLP-1 analog compound formulation to enter Phase III clinical trials. Furthermore, Hengrui has made multiple efforts around the GLP-1R target. In addition to HR17031, the once-daily GLP-1R agonist Nolitinib has also entered Phase III clinical trials. Additionally, Hengrui has advanced GLP-1R/GIPR agonist HRS9531 and small molecule GLP-1R agonist HRS-7535 to Phase II clinical trials.